A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume
Public ClinicalTrials.gov record NCT06734351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Evaluator and Subject-blinded, Randomized, Comparator-controlled, Parallel-design Study to Evaluate the Safety and Effectiveness of NOA VOLUME Compared to JUVÉDERM® VOLUMA® XC for Improvement of Mid-face Volume
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Facial fullness is often regarded as a characteristic feature of a youthful face. Chronic reduction of collagen, elastin, and glycosaminoglycans contribute to the facial volume loss that characterizes the aging face. Volume restoration by replacing or augmenting soft tissue is critical to successful facial rejuvenation. NOA VOLUME is a crosslinked Hyaluronic Acid (HA) injectable gel formulated with lidocaine that was developed to provide a safe, minimally invasive method of improving mid-face volume deficit. The purpose of this study is to assess safety and effectiveness of NOA VOLUME in adult participants seeking improvement of mid-face volume compared to JUVÉDERM VOLUMA XC (VOLUMA XC). NOA VOLUME is an investigational device being developed for the improvement of mid-face volume. There will be 2 cohorts in this study. Participants will receive either NOA VOLUME or VOLUMA XC. Around 231 adult participants seeking improvement of mid-face volume will be enrolled in the study at approximately 15 sites in the United States. Participants will receive either NOA VOLUME or VOLUMA XC injections in the cheek area on Day 1. Participants will receive optional touch-up treatment at Day 31 and optional repeat treatment at Month 18 and will be followed up for up to 31 months.
Study identification
- NCT ID
- NCT06734351
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 231 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2024
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2029
- Last update posted
- Jun 17, 2026
2024 – 2029
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Total Skin and Beauty Dermatology Center /ID# 258164 | Birmingham | Alabama | 35205 | Recruiting |
| Advanced Research Associates - Glendale /ID# 276812 | Glendale | Arizona | 85308 | Recruiting |
| West Dermatology La Jolla /ID# 278590 | San Diego | California | 92121 | Recruiting |
| Susan H. Weinkle MD /ID# 258160 | Bradenton | Florida | 34209-5642 | Recruiting |
| Hevia Cosmetic Dermatology /ID# 258165 | Coral Gables | Florida | 33134 | Recruiting |
| Skin Research Institute LLC /ID# 258158 | Coral Gables | Florida | 33146-1837 | Recruiting |
| Atlanta Biomedical Clinical Research /ID# 261210 | Atlanta | Georgia | 30331-2160 | Recruiting |
| Pure Dermatology /ID# 258168 | Metairie | Louisiana | 70001 | Recruiting |
| Aesthetic Center at Woodholme /ID# 258166 | Baltimore | Maryland | 21208-6391 | Recruiting |
| Edwin F. Williams III, MD FACS of LATHAM P.C. D/B/A THE REJUVA CENTER /ID# 261211 | Latham | New York | 12110 | Recruiting |
| Jane Yoo MD /ID# 279811 | New York | New York | 10019 | Recruiting |
| Northwest Dermatology Institute /ID# 258167 | Portland | Oregon | 97210-2859 | Recruiting |
| Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 258156 | Austin | Texas | 78746-4720 | Recruiting |
| SkinDC /ID# 258163 | Arlington | Virginia | 22209 | Recruiting |
| EthiQ2 Research, LLC /ID# 258906 | Brookfield | Wisconsin | 53005 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06734351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 17, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06734351 live on ClinicalTrials.gov.